A new discussion paper from MTPConnect reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies drive significant investment and rapid expansion.
Radiopharmaceuticals are precision nuclear medicines used for medical imaging and treatment. These radioactive drugs target specific organs or tissues, allowing doctors to diagnose and deliver targeted therapies for diseases such as cancer.
The discussion paper, ‘From Mines to Medicines. Australia’s Radiopharmaceuticals Future’ highlights Australia’s competitive edge on the rest of the world, starting with the raw material – mining assets and its waste products – found in South Australia. It outlines a national roadmap to maximise this opportunity and leverage our competitive edge.
Click here to book an appointment with our Director Dana Bell.